- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
U.S. Pharmaceuticals & Biotech Strong Balance Sheet with Growth Potential
Results
12
1 new
Stocks with plenty of capacity to fund future growth
12 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
NBIX | US$139.44 | 1.8% | 5.8% | US$14.1b | US$165.84 | PE36.6x | E30.9% | n/a | ||
INCY | US$69.23 | -0.9% | 10.3% | US$13.3b | US$79.38 | PE410.6x | E46.9% | n/a | ||
EXEL New | US$33.81 | 1.0% | 40.9% | US$9.7b | US$33.38 | PE20.7x | E17.2% | n/a | ||
CORT | US$52.47 | 3.1% | 61.5% | US$5.5b | US$74.90 | PE39.1x | E41.4% | n/a | ||
KRYS | US$159.29 | -1.0% | 28.4% | US$4.6b | US$207.78 | PE87.5x | E41.2% | n/a | ||
ADMA | US$17.45 | -1.5% | 286.1% | US$4.1b | US$24.62 | PE60.5x | E30.7% | n/a | ||
VCEL | US$57.33 | 0.5% | 61.0% | US$2.8b | US$64.25 | PE797.6x | E51.6% | n/a | ||
ACAD | US$16.95 | -1.3% | -45.9% | US$2.8b | US$25.11 | PE21.9x | E28.0% | n/a | ||
LGND | US$109.19 | -4.1% | 52.9% | US$2.1b | US$144.00 | PE45.6x | E26.9% | n/a | ||
HRMY | US$34.20 | -2.1% | 5.9% | US$2.0b | US$53.88 | PE15.9x | E34.5% | n/a | ||
CDXC | US$5.52 | 4.2% | 286.0% | US$422.6m | US$7.96 | PE284.6x | E81.8% | n/a | ||
BSEM | US$12.65 | -6.6% | 115.9% | US$210.2m | US$32.50 | PE13.3x | E33.8% | n/a |
Page 1 of 1